Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.40)
# 290
Out of 5,182 analysts
241
Total ratings
44.24%
Success rate
26.65%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics | Downgrades: Neutral | n/a | $9.38 | - | 10 | Mar 26, 2026 | |
| RNAC Cartesian Therapeutics | Upgrades: Overweight | $16 | $6.28 | +154.78% | 1 | Mar 9, 2026 | |
| QURE uniQure | Upgrades: Neutral | $55 → $9 | $17.50 | -48.57% | 11 | Mar 2, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $153 → $125 | $65.09 | +92.04% | 10 | Feb 17, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Maintains: Overweight | $11 → $19 | $7.05 | +169.69% | 2 | Jan 15, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | $21 → $15 | $14.45 | +0.38% | 8 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Overweight | $42 → $48 | $21.00 | +128.57% | 2 | Dec 17, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $7.95 | +201.89% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $5.66 | +235.69% | 2 | Dec 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $9.59 | +150.26% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $38 | $27.70 | +37.18% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $63 | $50.37 | +25.07% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $22.77 | +361.13% | 20 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $68.96 | +71.11% | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $74 | $54.04 | +36.94% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $7.76 | +106.19% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $32.64 | -8.07% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $23.45 | +245.42% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.70 | +49.09% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $52.20 | +135.65% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $4.19 | +2,047.97% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $0.33 | +2,006.53% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $31.22 | +114.61% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.13 | +311.62% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.65 | +202.46% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $1.93 | +469.95% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $4.91 | +266.60% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $0.69 | +1,928.69% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $0.68 | +1,805.60% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.10 | +1,809.09% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.57 | +282.17% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $0.22 | +9,180.74% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $7.01 | +228.10% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $0.76 | +117,932.79% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $2.02 | +4,107.92% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.75 | +2,566.67% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $1.60 | +11,150.00% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.81 | +509.42% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.45 | +4,037.93% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $0.82 | +10,889.01% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.52 | +483,585.22% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $3.42 | +88,788.89% | 1 | Jan 9, 2020 |
ADMA Biologics
Mar 26, 2026
Downgrades: Neutral
Price Target: n/a
Current: $9.38
Upside: -
Cartesian Therapeutics
Mar 9, 2026
Upgrades: Overweight
Price Target: $16
Current: $6.28
Upside: +154.78%
uniQure
Mar 2, 2026
Upgrades: Neutral
Price Target: $55 → $9
Current: $17.50
Upside: -48.57%
Disc Medicine
Feb 17, 2026
Maintains: Overweight
Price Target: $153 → $125
Current: $65.09
Upside: +92.04%
Eupraxia Pharmaceuticals
Jan 15, 2026
Maintains: Overweight
Price Target: $11 → $19
Current: $7.05
Upside: +169.69%
Amicus Therapeutics
Dec 19, 2025
Downgrades: Neutral
Price Target: $21 → $15
Current: $14.45
Upside: +0.38%
DBV Technologies
Dec 17, 2025
Maintains: Overweight
Price Target: $42 → $48
Current: $21.00
Upside: +128.57%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $7.95
Upside: +201.89%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $5.66
Upside: +235.69%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $9.59
Upside: +150.26%
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $27.70
Upside: +37.18%
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $50.37
Upside: +25.07%
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $22.77
Upside: +361.13%
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $68.96
Upside: +71.11%
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $54.04
Upside: +36.94%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $7.76
Upside: +106.19%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $32.64
Upside: -8.07%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $23.45
Upside: +245.42%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $4.70
Upside: +49.09%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $52.20
Upside: +135.65%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $4.19
Upside: +2,047.97%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $0.33
Upside: +2,006.53%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $31.22
Upside: +114.61%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $4.13
Upside: +311.62%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.65
Upside: +202.46%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.93
Upside: +469.95%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $4.91
Upside: +266.60%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $0.69
Upside: +1,928.69%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $0.68
Upside: +1,805.60%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.10
Upside: +1,809.09%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.57
Upside: +282.17%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $0.22
Upside: +9,180.74%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $7.01
Upside: +228.10%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $0.76
Upside: +117,932.79%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.02
Upside: +4,107.92%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.75
Upside: +2,566.67%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $1.60
Upside: +11,150.00%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.81
Upside: +509.42%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.45
Upside: +4,037.93%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $0.82
Upside: +10,889.01%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.52
Upside: +483,585.22%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $3.42
Upside: +88,788.89%